| Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma E Rassy, R Flippot, L Albiges Therapeutic advances in medical oncology 12, 1758835920907504, 2020 | 133 | 2020 |
| Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond S Boussios, C Abson, M Moschetta, E Rassy, A Karathanasi, T Bhat, ... Drugs in R&D 20, 55-73, 2020 | 127 | 2020 |
| Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review S Boussios, P Karihtala, M Moschetta, A Karathanasi, A Sadauskaite, ... Diagnostics 9 (3), 87, 2019 | 122 | 2019 |
| The currently declining incidence of cancer of unknown primary E Rassy, N Pavlidis Cancer epidemiology 61, 139-141, 2019 | 115 | 2019 |
| BRCA mutations in ovarian and prostate cancer: bench to bedside S Boussios, E Rassy, M Moschetta, A Ghose, S Adeleke, E Sanchez, ... Cancers 14 (16), 3888, 2022 | 105 | 2022 |
| Applications of proteomics in ovarian cancer: dawn of a new era A Ghose, SVN Gullapalli, N Chohan, A Bolina, M Moschetta, E Rassy, ... Proteomes 10 (2), 16, 2022 | 101 | 2022 |
| Progress in refining the clinical management of cancer of unknown primary in the molecular era E Rassy, N Pavlidis Nature reviews Clinical oncology 17 (9), 541-554, 2020 | 90 | 2020 |
| Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach S Boussios, P Karihtala, M Moschetta, C Abson, A Karathanasi, ... Investigational new drugs 38, 181-193, 2020 | 89 | 2020 |
| New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? E Rassy, P Parent, F Lefort, S Boussios, G Baciarello, N Pavlidis Critical reviews in oncology/hematology 147, 102882, 2020 | 85 | 2020 |
| Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets E Ioannidou, M Moschetta, S Shah, JS Parker, MA Ozturk, ... International journal of molecular sciences 22 (18), 9926, 2021 | 76 | 2021 |
| Unraveling the wide spectrum of melanoma biomarkers A Revythis, S Shah, M Kutka, M Moschetta, MA Ozturk, G Pappas-Gogos, ... Diagnostics 11 (8), 1341, 2021 | 74 | 2021 |
| Exploring the biological hallmarks of cancer of unknown primary: where do we stand today? E Rassy, T Assi, N Pavlidis British journal of cancer 122 (8), 1124-1132, 2020 | 72 | 2020 |
| Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment E El Rassy, A Botticella, J Kattan, C Le Péchoux, B Besse, L Hendriks Cancer treatment reviews 68, 69-79, 2018 | 72 | 2018 |
| Melanoma of unknown primary: New perspectives for an old story S Boussios, E Rassy, E Samartzis, M Moschetta, M Sheriff, ... Critical reviews in oncology/hematology 158, 103208, 2021 | 69 | 2021 |
| Advances in ovarian cancer treatment beyond PARP inhibitors F Aliyuda, M Moschetta, A Ghose, K Sofia Rallis, M Sheriff, E Sanchez, ... Current Cancer Drug Targets 23 (6), 433-446, 2023 | 68 | 2023 |
| Wise management of ovarian cancer: on the cutting edge S Boussios, C Mikropoulos, E Samartzis, P Karihtala, M Moschetta, ... Journal of personalized medicine 10 (2), 41, 2020 | 65 | 2020 |
| The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry N Pavlidis, E Rassy, JB Vermorken, T Assi, J Kattan, S Boussios, ... Cancer epidemiology 75, 102045, 2021 | 63 | 2021 |
| Comprehensive management of HPV‐related squamous cell carcinoma of the head and neck of unknown primary E Rassy, P Nicolai, N Pavlidis Head & Neck 41 (10), 3700-3711, 2019 | 62 | 2019 |
| Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic A Bizot, M Karimi, E Rassy, PE Heudel, C Levy, L Vanlemmens, C Uzan, ... British journal of cancer 125 (11), 1486-1493, 2021 | 60 | 2021 |
| Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review T Assi, J Kattan, E Rassy, H Nassereddine, F Farhat, C Honore, ... Critical Reviews in Oncology/Hematology 153, 103029, 2020 | 60 | 2020 |